Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2021 4
2022 7
2023 15
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Results by year

Filters applied: Clinical Trial, Meta-Analysis, Randomized Controlled Trial, Review, Systematic Review, in the last 10 years. Clear all
Page 1
Did you mean (consumo) OR (mosunetuzumab) (176 results)?
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study.
Budde LE, Sehn LH, Matasar M, Schuster SJ, Assouline S, Giri P, Kuruvilla J, Canales M, Dietrich S, Fay K, Ku M, Nastoupil L, Cheah CY, Wei MC, Yin S, Li CC, Huang H, Kwan A, Penuel E, Bartlett NL. Budde LE, et al. Lancet Oncol. 2022 Aug;23(8):1055-1065. doi: 10.1016/S1470-2045(22)00335-7. Epub 2022 Jul 5. Lancet Oncol. 2022. PMID: 35803286 Clinical Trial.
BACKGROUND: Mosunetuzumab is a CD20 CD3 T-cell-engaging bispecific monoclonal antibody that redirects T cells to eliminate malignant B cells. In a phase 1 study, mosunetuzumab was well tolerated and active in patients with relapsed or refractory B-cell lymphoma. ...
BACKGROUND: Mosunetuzumab is a CD20 CD3 T-cell-engaging bispecific monoclonal antibody that redirects T cells to eliminate malignant …
Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study.
Budde LE, Assouline S, Sehn LH, Schuster SJ, Yoon SS, Yoon DH, Matasar MJ, Bosch F, Kim WS, Nastoupil LJ, Flinn IW, Shadman M, Diefenbach C, O'Hear C, Huang H, Kwan A, Li CC, Piccione EC, Wei MC, Yin S, Bartlett NL. Budde LE, et al. J Clin Oncol. 2022 Feb 10;40(5):481-491. doi: 10.1200/JCO.21.00931. Epub 2021 Dec 16. J Clin Oncol. 2022. PMID: 34914545 Free PMC article. Clinical Trial.
PURPOSE: Mosunetuzumab is a bispecific antibody targeting CD20 and CD3 that redirects T cells to engage and eliminate malignant B cells and is being developed for relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs). METHODS: This first-in-human trial (Clinic …
PURPOSE: Mosunetuzumab is a bispecific antibody targeting CD20 and CD3 that redirects T cells to engage and eliminate malignant B cel …
Mosunetuzumab: First Approval.
Kang C. Kang C. Drugs. 2022 Jul;82(11):1229-1234. doi: 10.1007/s40265-022-01749-5. Drugs. 2022. PMID: 35947358 Review.
Mosunetuzumab (Lunsumio()), an anti-CD20/CD3 T-cell engaging bispecific antibody, is being developed by Roche for the treatment of relapsed or refractory follicular lymphoma. ...This article summarizes the milestones in the development of mosunetuzumab leadin …
Mosunetuzumab (Lunsumio()), an anti-CD20/CD3 T-cell engaging bispecific antibody, is being developed by Roche for the treatmen …
Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment.
Bock AM, Nowakowski GS, Wang Y. Bock AM, et al. Curr Treat Options Oncol. 2022 Feb;23(2):155-170. doi: 10.1007/s11864-021-00925-1. Epub 2022 Feb 19. Curr Treat Options Oncol. 2022. PMID: 35182296 Review.
The development of CD19 CD3 BsAbs such as blinatumomab was met with significant challenges due to dose-limiting neurologic side effects. However, several CD20 CD3 BsAbs including odronextamab, mosunetuzumab, glofitamab, and epcoritamab emerged recently. They have favorable …
The development of CD19 CD3 BsAbs such as blinatumomab was met with significant challenges due to dose-limiting neurologic side effects. How …
Role of Bispecific Antibodies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the CART Era.
González Barca E. González Barca E. Front Immunol. 2022 Jul 19;13:909008. doi: 10.3389/fimmu.2022.909008. eCollection 2022. Front Immunol. 2022. PMID: 35928819 Free PMC article. Review.
The results of different phase 1 trials with BsAbs, including mosunetuzumab, glofitamab, epcoritamab and odeonextamab, have been recently published. ...
The results of different phase 1 trials with BsAbs, including mosunetuzumab, glofitamab, epcoritamab and odeonextamab, have been rece …
Targeted Treatment of Relapsed or Refractory Follicular Lymphoma: Focus on the Therapeutic Potential of Mosunetuzumab.
Lopedote P, Shadman M. Lopedote P, et al. Cancer Manag Res. 2023 Mar 14;15:257-264. doi: 10.2147/CMAR.S381493. eCollection 2023. Cancer Manag Res. 2023. PMID: 36941881 Free PMC article. Review.
The recently approved T-cell-dependent bispecific antibody mosunetuzumab showed promising results and manageable toxicities for patients with relapsed or refractory follicular lymphoma. ...Given the recent withdrawal from the market of PI3K inhibitors and the practical cha …
The recently approved T-cell-dependent bispecific antibody mosunetuzumab showed promising results and manageable toxicities for patie …
Update on bi-specific monoclonal antibodies for blood cancers.
Shouse G. Shouse G. Curr Opin Oncol. 2023 Sep 1;35(5):441-445. doi: 10.1097/CCO.0000000000000966. Epub 2023 Jul 5. Curr Opin Oncol. 2023. PMID: 37551951 Review.
RECENT FINDINGS: Teclistamab, the beta-cell maturation antigen -targeted bispecific antibody has shown efficacy and tolerability in the fourth line setting for multiple myeloma. Mosunetuzumab, the CD20-targeted bispecific antibody has shown excellent response rates and dur …
RECENT FINDINGS: Teclistamab, the beta-cell maturation antigen -targeted bispecific antibody has shown efficacy and tolerability in the four …
Mosunetuzumab and lymphoma: latest updates from 2022 ASH annual meeting.
Cao Y, Marcucci EC, Budde LE. Cao Y, et al. J Hematol Oncol. 2023 Jun 28;16(1):69. doi: 10.1186/s13045-023-01462-0. J Hematol Oncol. 2023. PMID: 37381053 Free PMC article. Review.
As the first BsAb to receive regulatory approval for lymphoma, mosunetuzumab, an antiCD20/anti-CD3 BsAb, is an exciting new option for patients with relapsed or refractory (R/R) follicular lymphoma. ...Here we provided an overview of the latest clinical data on mosunetu …
As the first BsAb to receive regulatory approval for lymphoma, mosunetuzumab, an antiCD20/anti-CD3 BsAb, is an exciting new option fo …
Mosunetuzumab.
[No authors listed] [No authors listed] 2023 Nov 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2023 Nov 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 36701508 Free Books & Documents. Review.
No information is available on the clinical use of mosunetuzumab during breastfeeding. Because mosunetuzumab is a large protein molecule with a molecular weight of 146,000 Da, the amount in milk is likely to be very low.[1] It is also likely to be partially destroye …
No information is available on the clinical use of mosunetuzumab during breastfeeding. Because mosunetuzumab is a large protei …
Mosunetuzumab and the emerging role of T-cell-engaging therapy in follicular lymphoma.
Matarasso S, Assouline S. Matarasso S, et al. Future Oncol. 2023 Oct;19(31):2083-2101. doi: 10.2217/fon-2023-0274. Epub 2023 Oct 26. Future Oncol. 2023. PMID: 37882361 Review.
This review covers approved treatments for R/R FL and focuses on preclinical and clinical data available for mosunetuzumab (Lunsumio), with the goal of determining its role in the treatment of R/R FL. ...This review focuses on the design and testing of mosunetuzu …
This review covers approved treatments for R/R FL and focuses on preclinical and clinical data available for mosunetuzumab (Lunsum …
25 results